Vertex VERX 深 滬
等待開盤 11-04 09:30:00 美东时间
15.26
-0.570
-3.60%
華盛通- 最 高15.60
- 今 開15.60
- 成交量 138.91万股
- 最 低 15.03
- 昨 收 15.83
- 總市值 247.54万
- 52周最高 20.82
- 市盈率 靜 343.69
- 換手率 0.86%
- 52周最低 10.21
- 委 比 -42.53%
- 總股本 0.00亿
- 歷史最高 60.71
- 量 比 1.05
- 振 幅 3.60%
- 歷史最低 9.44
- 每 手 1
- 風險率 3.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday. The company posted quarterly earnings of $4.76 per share which missed the analyst consensus estimate of $4.82 per share. The company reported quarterly sales of $3.441 billion which beat the ana...
11-03 21:15
Vertex Inc收涨3.33%，成交额2409.22万美元
11月3日，Vertex Inc（VERX）收涨3.33%，报15.83美元，成交额2409.22万美元，市值25.68亿美元。 行情数据 • 开盘价：15....
11-03 06:19
Asure Software And Vertex Partner To Deliver Improved Payroll Tax Calculation And Compliance Offering To US Enterprise Market
Asure Software, Inc. (NASDAQ:ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced a strategic partnership designed to deliv...
11-02 21:10
Asure Software and Vertex Announce Strategic Alliance to Expand Payroll Tax Management Reach
Asure Software and Vertex announce a strategic partnership to enhance payroll tax calculation and compliance solutions in the U.S. enterprise market. The collaboration combines Vertex's tax calculation technology with Asure's infrastructure for tax filing, remittance, and compliance. This partnership aims to expand Asure's market share and provide a comprehensive end-to-end payroll tax solution. Both companies expect growth through new distributi...
11-02 13:01
打破部门壁垒的生物科技领军人物
杰夫・莱登在生物科技行业拥有一段堪称传奇的经历。2012 年，当时 Vertex 制药处境艰难，莱登出任首席执行官，彼时公司股价不足 40 美元。如今他担任...
10-28 00:22
AvePoint, the AI Trust Company, Announces the AvePoint Trust Platform to Govern, Secure, and Optimize AI
AvePoint introduced its Trust Platform, empowering organizations to govern, secure, and optimize AI across all agents, models, and vendors. The platform includes new AI Governance and Security capabilities for unified management, visibility, and compliance, as well as cost optimization tools to maximize AI investment returns. It supports Anthropic Claude, Windows, and server-hosted agents, offering backup, recovery, and lifecycle governance. AveP...
10-27 13:00
Vertex Inc收跌1.43%，成交额1560.85万美元
10月27日，Vertex Inc（VERX）收跌1.43%，报15.17美元，成交额1560.85万美元，市值24.61亿美元。 行情数据 • 开盘价：15...
10-27 05:22
Vertex Launches Vertex Sol
Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), the Decision-to-Defense™ global indirect tax and compliance company, today introduced Vertex Sōl™, a connected compliance experience that brings intelligence, workflows, decisions, and evidence together across the tax lifecycle. The transaction...
10-27 01:12
Vertex Introduces Vertex Sōl™, a Connected, AI-Powered Tax and Compliance Experience
Vertex, Inc. introduces Vertex Sōl™, a connected compliance experience that integrates AI, workflows, decisions, and evidence across the tax lifecycle. Designed to enhance visibility and control, Vertex Sōl helps tax teams manage transactions from determination to audit, ensuring transparency and the ability to govern AI-driven actions. It supports varying levels of AI trust, allowing professionals to review, override, or reverse decisions as nee...
10-26 17:01
Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30
– Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – – Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-...
10-24 01:43
